{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T17:15:54Z","timestamp":1779297354962,"version":"3.51.4"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:p>Immune checkpoint inhibitor therapy is effective only for a subset of patients with gastric cancer. Impaired neoantigen presentation caused by deficiency of human leukocyte antigen class I (HLA-I) has been reported as a common mechanism of immune evasion which is associated with resistance to immune checkpoint blockade. To elucidate the significance of HLA-I deficiency in gastric cancer with special focus on microsatellite instable (MSI) and Epstein-Barr virus (EBV)-positive tumors, we examined HLA-I expression on tumor cells and correlated the results with clinicopathologic features, programmed death-ligand 1 (PD-L1) expression, and degree of tumor-infiltrating immune cells. This study included 58 MSI, 44 EBV-positive, and 107 non-EBV non-MSI tumors for comparison. The frequency of HLA-I deficiency (\u22651% tumor cells) was significantly higher in MSI tumors (52%) compared with EBV-positive tumors (23%) and the other tumors (28%). In contrast, PD-L1 expression levels were highest in EBV-positive tumors, followed by MSI tumors, with the lowest prevalence in the other tumors in both Tumor Proportion Score and Combined Positive Score. HLA-I deficiency was significantly more frequent in advanced tumors (pT2-4) than in early tumors (pT1) in MSI and non-EBV non-MSI subtypes. In addition, the degree of CD8-positive cells infiltration was significantly reduced in HLA-I deficient tumor areas compared with HLA-I preserved tumor area within a tumor. Based on our observations, HLA-I, as well as PD-L1, should be considered as a common mechanism of immune escape especially in the MSI subtype, and therefore could be a biomarker predicting response to immune checkpoint inhibitor therapy in gastric cancer.<\/jats:p>","DOI":"10.1097\/pas.0000000000001779","type":"journal-article","created":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T18:12:17Z","timestamp":1627323137000},"page":"1213-1220","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":17,"title":["Human Leukocyte Antigen Class I Deficiency in Gastric Carcinoma"],"prefix":"10.1097","volume":"45","author":[{"given":"Akiko","family":"Iwasaki","sequence":"first","affiliation":[{"name":"Pathology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aya","family":"Shinozaki-Ushiku","sequence":"additional","affiliation":[{"name":"Pathology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Kunita","sequence":"additional","affiliation":[{"name":"Pathology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sho","family":"Yamazawa","sequence":"additional","affiliation":[{"name":"Pathology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuyoshi","family":"Sato","sequence":"additional","affiliation":[{"name":"Gastrointestinal Surgery, The University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroharu","family":"Yamashita","sequence":"additional","affiliation":[{"name":"Department of Digestive Surgery, Nihon University School of Medicine, Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Fukayama","sequence":"additional","affiliation":[{"name":"Asahi TelePathology Center, Asahi General Hospital, Asahi, Chiba Prefecture, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuyuki","family":"Seto","sequence":"additional","affiliation":[{"name":"Gastrointestinal Surgery, The University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuo","family":"Ushiku","sequence":"additional","affiliation":[{"name":"Pathology"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,7,26]]},"reference":[{"key":"R1-20250608","doi-asserted-by":"crossref","first-page":"e180013","DOI":"10.1001\/jamaoncol.2018.0013","article-title":"Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase II clinical KEYNOTE-059 Trial","volume":"4","author":"Fuchs","year":"2018","journal-title":"JAMA Oncol"},{"key":"R2-20250608","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1200\/JCO.2017.76.6212","article-title":"CheckMate-032 Study: efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer","volume":"36","author":"Janjigian","year":"2018","journal-title":"J Clin Oncol"},{"key":"R3-20250608","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","article-title":"Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Kang","year":"2017","journal-title":"Lancet"},{"key":"R4-20250608","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S1470-2045(16)00175-3","article-title":"Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial","volume":"17","author":"Muro","year":"2016","journal-title":"Lancet Oncol"},{"key":"R5-20250608","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1634\/theoncologist.2018-0221","article-title":"FDA approval summary: pembrolizumab for recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma expressing PD-L1","volume":"24","author":"Fashoyin-Aje","year":"2019","journal-title":"Oncologist"},{"key":"R6-20250608","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1097\/PAS.0000000000000698","article-title":"Programmed death-ligand 1 expression is common in gastric cancer associated with Epstein-Barr virus or microsatellite instability","volume":"40","author":"Ma","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"R7-20250608","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/modpathol.2016.202","article-title":"Overexpression and gene amplification of PD-L1 in cancer cells and PD-L1(+) immune cells in Epstein-Barr virus-associated gastric cancer: the prognostic implications","volume":"30","author":"Saito","year":"2017","journal-title":"Mod Pathol"},{"key":"R8-20250608","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.3892\/ijo.2015.2856","article-title":"Update on Epstein-Barr virus and gastric cancer (review)","volume":"46","author":"Shinozaki-Ushiku","year":"2015","journal-title":"Int J Oncol"},{"key":"R9-20250608","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1038\/s41591-018-0101-z","article-title":"Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer","volume":"24","author":"Kim","year":"2018","journal-title":"Nat Med"},{"key":"R10-20250608","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"R11-20250608","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/tan.12898","article-title":"Molecular mechanisms of HLA class I-mediated immune evasion of human tumors and their role in resistance to immunotherapies","volume":"88","author":"Seliger","year":"2016","journal-title":"HLA"},{"key":"R12-20250608","doi-asserted-by":"crossref","first-page":"1259.e11","DOI":"10.1016\/j.cell.2017.10.001","article-title":"Allele-specific HLA loss and immune escape in lung cancer evolution","volume":"171","author":"McGranahan","year":"2017","journal-title":"Cell"},{"key":"R13-20250608","doi-asserted-by":"crossref","first-page":"eaar3342","DOI":"10.1126\/scitranslmed.aar3342","article-title":"MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma","volume":"10","author":"Rodig","year":"2018","journal-title":"Sci Transl Med"},{"key":"R14-20250608","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1038\/s41416-020-0793-y","article-title":"Differential prognostic impact of CD8(+) T cells based on human leucocyte antigen I and PD-L1 expression in microsatellite-unstable gastric cancer","volume":"122","author":"Kwak","year":"2020","journal-title":"Br J Cancer"},{"key":"R15-20250608","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1007\/s00262-019-02410-z","article-title":"Clinicopathologic significance of human leukocyte antigen class I expression in patients with stage II and III gastric cancer","volume":"68","author":"Park","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"R16-20250608","doi-asserted-by":"crossref","first-page":"330","DOI":"10.5858\/arpa.2018-0043-OA","article-title":"Clinical utility of the combined positive score for programmed death ligand-1 expression and the approval of pembrolizumab for treatment of gastric cancer","volume":"143","author":"Kulangara","year":"2019","journal-title":"Arch Pathol Lab Med"},{"key":"R17-20250608","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1440-1827.2012.02789.x","article-title":"Establishment of a monoclonal anti-pan HLA class I antibody suitable for immunostaining of formalin-fixed tissue: unusually high frequency of down-regulation in breast cancer tissues","volume":"62","author":"Torigoe","year":"2012","journal-title":"Pathol Int"},{"key":"R18-20250608","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1097\/01.MP.0000076980.73826.C0","article-title":"Lymphocyte-rich gastric cancer: associations with Epstein-Barr virus, microsatellite instability, histology, and survival","volume":"16","author":"Grogg","year":"2003","journal-title":"Mod Pathol"},{"key":"R19-20250608","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.trecan.2016.02.004","article-title":"The immune biology of microsatellite-unstable cancer","volume":"2","author":"Kloor","year":"2016","journal-title":"Trends Cancer"},{"key":"R20-20250608","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nature13480","article-title":"Comprehensive molecular characterization of gastric adenocarcinoma","volume":"513","year":"2014","journal-title":"Nature"},{"key":"R21-20250608","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.coi.2018.03.006","article-title":"The transition from HLA-I positive to HLA-I negative primary tumors: the road to escape from T-cell responses","volume":"51","author":"Aptsiauri","year":"2018","journal-title":"Curr Opin Immunol"},{"key":"R22-20250608","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1158\/2159-8290.CD-17-1327","article-title":"Genetic mechanisms of immune evasion in colorectal cancer","volume":"8","author":"Grasso","year":"2018","journal-title":"Cancer Discov"},{"key":"R23-20250608","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov"},{"key":"R24-20250608","doi-asserted-by":"crossref","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci Signal"},{"key":"R26-20250608","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1111\/j.1349-7006.2007.00558.x","article-title":"HLA class I antigen expression is associated with a favorable prognosis in early stage non-small cell lung cancer","volume":"98","author":"Kikuchi","year":"2007","journal-title":"Cancer Sci"},{"key":"R27-20250608","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1158\/1078-0432.498.11.2","article-title":"Control of T-cell-mediated immune response by HLA class I in human pancreatic carcinoma","volume":"11","author":"Ryschich","year":"2005","journal-title":"Clin Cancer Res"},{"key":"R28-20250608","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1038\/s41467-017-01062-w","article-title":"Resistance to checkpoint blockade therapy through inactivation of antigen presentation","volume":"8","author":"Sade-Feldman","year":"2017","journal-title":"Nat Commun"},{"key":"R29-20250608","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to PD-1 blockade in melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N Engl J Med"},{"key":"R30-20250608","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s00262-020-02506-x","article-title":"Tumor mutational load, CD8+ T cells, expression of PD-L1 and HLA class I to guide immunotherapy decisions in NSCLC patients","volume":"69","author":"Hurkmans","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"R31-20250608","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1158\/2159-8290.CD-20-0672","article-title":"Somatic HLA class I loss is a widespread mechanism of immune evasion which refines the use of tumor mutational burden as a biomarker of checkpoint inhibitor response","volume":"11","author":"Montesion","year":"2021","journal-title":"Cancer Discov"},{"key":"R32-20250608","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1007\/s00262-019-02341-9","article-title":"MHC class-I downregulation in PD-1\/PD-L1 inhibitor refractory Merkel cell carcinoma and its potential reversal by histone deacetylase inhibition: a case series","volume":"68","author":"Ugurel","year":"2019","journal-title":"Cancer Immunol Immunother"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000001779","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T21:05:37Z","timestamp":1749416737000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000001779"}},"subtitle":["An Adaptive Immune Evasion Strategy Most Common in Microsatellite Instable Tumors"],"short-title":[],"issued":{"date-parts":[[2021,7,26]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000001779","relation":{},"ISSN":["0147-5185"],"issn-type":[{"value":"0147-5185","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7,26]]}}}